{
  "type": "hyp",
  "text": "Abnormal NF-kappaB activation after stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort. Activation of NF-kappaB in peripheral blood T cells was inducible during cytokine therapy in four of six individuals who displayed impaired NF-kappaB activation.\n",
  "self": {
    "NER": {
      "answers": [
        "phorbol myristate acetate/ionomycin",
        "59%",
        "17",
        "28",
        "four",
        "six"
      ],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": [
          "What was the only treatment that was found to cause NF-kappaB activation",
          "What percentage of patients had abnormal NF-kappaB activation after stimulation with",
          "How many patients had a phenotype of NF-kappaB activ",
          "What was the average age of the patients in the study?",
          "How many of the patients who had impaired NF-kappaB activation were found",
          "How many individuals showed impaired NF-kappaB activation?"
        ]
      }
    },
    "NOUN": {
      "answers": [
        "Abnormal NF-kappaB activation",
        "stimulation",
        "phorbol myristate acetate",
        "/ionomycin",
        "anti-CD3 monoclonal antibody",
        "59%",
        "patients",
        "the advanced age",
        "the study cohort",
        "Activation",
        "NF-kappaB",
        "peripheral blood T cells",
        "cytokine therapy",
        "four of six individuals",
        "who",
        "impaired NF-kappaB activation"
      ],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": [
          "What was found in 59% of patients?",
          "What was abnormally triggered after?",
          "What was used to stimulate NF-kappaB?",
          "What was the only drug that did not cause NF-kappaB activation?",
          "What was found in 59% of patients?",
          "What percentage of patients had abnormal NF-kappaB activation after stimulation with",
          "What percentage of patients had abnormal NF-kappaB activation?",
          "What was not accounted for in the study?",
          "What was not accounted for by the advanced age of the study?",
          "What was found in 59% of patients?",
          "What was found to be abnormally activated in 59% of patients?",
          "What type of cells were inducible during cytokine therapy?",
          "What was inducible in 4 of 6 individuals?",
          "How many individuals showed impaired NF-kappaB activation?",
          "What group of patients showed impaired NF-kappaB activation?",
          "What was found in 59% of patients?"
        ]
      }
    }
  },
  "asked": {
    "What activated platelets increased MCP-1 secretion and ICAM-1 surface expression?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0014769434928894043,
        "ground_truth": {
          "ADP": {
            "bertscore": 0.6812801361083984,
            "f1": 0
          }
        }
      }
    },
    "What secretion was significantly increased in the presence of ADP-activated platelets?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.00010883808135986328,
        "ground_truth": {
          "MCP-1": {
            "bertscore": 0.660986602306366,
            "f1": 0
          }
        }
      }
    },
    "What type of transcriptional activity was enhanced in the presence of ADP-activated platelets": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0038671493530273438,
        "ground_truth": {
          "kappaB-dependent": {
            "bertscore": 0.6545458436012268,
            "f1": 0
          }
        }
      }
    },
    "What was the most significant effect of ADP-activated platelets on surface expression?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.00024014711380004883,
        "ground_truth": {
          "the presence": {
            "bertscore": 0.7024357914924622,
            "f1": 0
          }
        }
      }
    },
    "What increased MCP-1 secretion and ICAM-1 surface expression?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.003995358943939209,
        "ground_truth": {
          "ADP-activated platelets": {
            "bertscore": 0.6214054822921753,
            "f1": 0
          },
          "activated platelets": {
            "bertscore": 0.6570233702659607,
            "f1": 0
          }
        }
      }
    },
    "What was significantly increased in the presence of ADP-activated platelets?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 7.30752944946289e-05,
        "ground_truth": {
          "both MCP-1 secretion": {
            "bertscore": 0.6430342793464661,
            "f1": 0
          },
          "ICAM-1 surface expression": {
            "bertscore": 0.6243892908096313,
            "f1": 0
          }
        }
      }
    },
    "What was the only other type of platelets that significantly increased MCP-1 secretion and": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.008910417556762695,
        "ground_truth": {
          "nonstimulated platelets": {
            "bertscore": 0.6780245304107666,
            "f1": 0
          }
        }
      }
    },
    "What was the significance of the increase in MCP-1 secretion and ICAM-1 surface": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.008609175682067871,
        "ground_truth": {
          "P<0.02": {
            "bertscore": 0.6458728313446045,
            "f1": 0
          }
        }
      }
    },
    "What was enhanced in the presence of ADP-activated platelets?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.00021642446517944336,
        "ground_truth": {
          "Activation": {
            "bertscore": 0.72251957654953,
            "f1": 0
          },
          "kappaB-dependent transcriptional activity": {
            "bertscore": 0.609296441078186,
            "f1": 0
          }
        }
      }
    },
    "What is the NF-kappaB?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.012855708599090576,
        "ground_truth": {
          "the transcription factor": {
            "bertscore": 0.6422821879386902,
            "f1": 0
          }
        }
      }
    },
    "What transcription factor was increased in the presence of ADP-activated platelets?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 9.78708267211914e-05,
        "ground_truth": {
          "nuclear factor-kappaB": {
            "bertscore": 0.6161284446716309,
            "f1": 0
          }
        }
      }
    },
    "What transcription factor was activated in the presence of ADP-activated platelets?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0006747245788574219,
        "ground_truth": {
          "(NF-kappaB": {
            "bertscore": 0.6411395072937012,
            "f1": 0
          }
        }
      }
    },
    "What method was used to determine the activation of the transcription factor nuclear factor-kappa": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.32829737663269043,
        "ground_truth": {
          "electrophoretic mobility shift assay": {
            "bertscore": 0.6640233993530273,
            "f1": 0
          }
        }
      }
    }
  }
}